D-0051-2027 Class II Ongoing

Recalled by Pfizer — Manhattan, NY

FDA drug recall D-0051-2027 was initiated by Pfizer on Sep 29, 2026 and is designated Class II. Reason for recall: Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing. The recall status is ongoing. Affected quantity: 134 1000-count bottles.

Recall details

Product Type
Drugs
Report Date
Oct 28, 2026
Initiation Date
Sep 29, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
134 1000-count bottles

Product description

Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 1000-count bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-10

Reason for recall

Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.

Distribution pattern

US Nationwide and Puerto Rico

Code information

Lot # 24W07, Exp: 11/30/2026

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0051-2027
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0051-2027. Report a data issue: hello@regdatalab.com.